Early work indicates drug used to treat alcoholism may help those with Fragile X and autism

Apr 04, 2011

In small, early clinical trials, adults and children with autism and Fragile X syndrome have shown improved communication and social behavior when treated with acamprosate, according to Craig Erickson, M.D., assistant professor of psychiatry at the Indiana University School of Medicine and chief of the Riley Hospital for Children Christian Sarkine Autism Treatment Center at Indiana University Health.

Acamprosate, which affects chemicals in the brain by blocking certain receptors associated with mental health, has approval from the for the treatment of alcoholism in adults.

Dr. Erickson is the inventor on a pending utility patent for the use of acamprosate as a for Fragile X syndrome, the most common inherited form of and the most frequent single gene cause of autism.

"We have been treating small numbers of both adults and children," said Erickson. "We have observed improvements in eye contact, and speech. This is very early work, but it appears promising.

"We have a lot to do. We need to determine appropriate doses and forms for the best drug delivery. Larger studies will be needed to determine effectiveness and tolerability. And we expect to find many interesting things along the road, for example whether this drug could work better in those with Fragile X who have autism than in those whose autism is from an unknown cause."

In November 2010 Dr. Erickson and colleagues reported in the on the first trial of acamprosate in adults with Fragile X syndrome and autism. In the three patients studied, acamprosate was associated with improved linguistic abilities. During five months of treatment all three showed unexpected marked communication improvement.

In a study supported by the Indiana University Clinical and Translational Sciences Institute, Dr. Erickson is currently recruiting five-to-17-year-old children with Fragile X syndrome to a clinical trial designed to learn if acamprosate reduces various symptoms including inattention, hyperactivity, language impairment, irritability, and social deficits. In addition to investigating the effectiveness and tolerability of acamprosate in youth with Fragile X syndrome, IU School of Medicine researchers are assessing neurobiological differences between Fragile X syndrome and autism spectrum disorders of unknown cause.

Fragile X syndrome is the most common inherited form of developmental disability. Fragile X syndrome is inherited from a carrier parent, most frequently the mother. Up to two thirds of individuals with Fragile X syndrome display evidence of autism spectrum disorders.

"Dr. Erickson's research and work in this area is unique. The Indiana University Research and Technology Corporation has applied for a use patent because, while we are far from definitive knowledge and treatment, as early data is acquired, we believe this drug has real potential as a therapy for both children and adults with autism," said Bradley Fravel, Ph.D., MBA, an IURTC senior technology manager. IURTC works to enhance the research and development capability of Indiana University, creating new Indiana-based companies, and provides support for entrepreneurial development.

Dr. Erickson strongly cautions that while preliminary data on acamprosate in individuals with appears promising, large scale multi-center clinical trials of acamprosate are needed to determine whether it can help those with Fragile X and autism.

Explore further: Ebola: timeline of a ruthless killer

Provided by Indiana University School of Medicine

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Secret funding fosters hope for new drugs for autism

Sep 15, 2010

Funding from an anonymous wealthy family has been the secret to progress, at long last, in developing drugs that show promise for helping millions of people worldwide with Fragile X syndrome, the most common genetic cause ...

Measuring intellectual disability

Jun 24, 2009

Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. ...

Recommended for you

Ebola-hit Liberia delays school reopening

3 hours ago

Liberia's education ministry said on Sunday it had postponed by two weeks the reopening of the country's schools, which were closed six months ago to limit the spread of the Ebola virus.

Ebola: timeline of a ruthless killer

12 hours ago

Here are key dates in the current Ebola epidemic, the worst ever outbreak of the haemorrhagic fever which first surfaced in 1976 in the Democratic Republic of Congo (DRC).

Ebola reveals shortcomings of African solidarity

Jan 31, 2015

As Africa's leaders meet in Ethiopia to discuss the Ebola crisis, expectations of firm action will be tempered by criticism over the continent's poor record in the early stages of the epidemic.

Second bird flu case confirmed in Canada

Jan 30, 2015

The husband of a Canadian who was diagnosed earlier this week with bird flu after returning from a trip to China has also tested positive for the virus, health officials said Friday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.